Xenotransplantation Products Makers Should Not Be Strangers To FDA Rules
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers and clinical investigators of products derived from human and animal tissues should pay special attention to FDA rules and ensure that human research subjects give their full informed consent, according to Philip Noguchi, MD, head of the Division of Cellular and Gene Therapies in the Office of Therapeutics Research and Review at FDA's Center for Biologics Evaluation and Research.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.